Jazz Pharmaceuticals Acquires Actio Biosciences to Expand Rare Epilepsy Portfolio
Jazz Pharmaceuticals announced today its acquisition of Actio Biosciences, expanding its portfolio of rare epilepsy treatments. The transaction includes an upfront payment of $820 million.
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a company focused on developing treatments for rare forms of epilepsy.
The acquisition will add ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, to Jazz's pipeline. Jazz plans to leverage its existing expertise in the development and commercialization of treatments for rare and severe epilepsies.
The transaction involves an upfront payment of $820 million to Actio Biosciences. Further details regarding the financing structure or potential milestone payments were not immediately disclosed. This move is expected to bolster Jazz Pharmaceuticals' presence in the rare neurological disease market.
The deal is anticipated to close by the end of 2026, subject to customary closing conditions. Jazz Pharmaceuticals has a history of focusing on treatments for rare conditions, including narcolepsy and acute promyelocytic leukemia.